• Moderna COVID-19 Vaccine Candidate Meets Primary Efficacy Endpoint americanpharmaceuticalreview
    November 17, 2020
    Moderna announced the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the ...
PharmaSources Customer Service